New Evidence, Guidelines Support Mavacamten Use in Hypertrophic Cardiomyopathy

A trio of studies and new guidelines presented at the ESC Congress 2023 highlight advancement in the management of hypertrophic cardiomyopathy, particularly with use of mavacamten.

Related Keywords

United States ,China ,Amy Sehnert ,Pablo Garc ,Milind Desai ,European Society Of Cardiology ,Bristol Myers Squibb ,European Union ,Heart Failure Clinical Development ,European Society ,Bristol Myers ,Inherited Cardiac Diseases ,Heart Failure Unit ,Septal Reduction ,Eur Heart ,Mavacamten ,Camzyos ,Phcm ,Johcm ,Hypertrophic Cardiomyopathy ,